Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Real-world impact and effectiveness of MenACWY-TT

R. Villena, P. Kriz, M. Tin Tin Htar, C. Burman, J. Findlow, P. Balmer, L. Jodar

. 2023 ; 19 (2) : 2251825. [pub] 2023Aug01

Language English Country United States

Document type Journal Article, Review, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23016628

In response to escalating cases of serogroup W (MenW) invasive meningococcal disease (IMD), multiple countries introduced quadrivalent conjugate MenACWY vaccines into their national immunization programs (NIPs). Here, we summarize the real-world impact and vaccine effectiveness (VE) data of MenACWY-TT from Chile, England, the Netherlands, and Australia. Incidence rate reductions (IRRs) and VE from baseline to post-NIP period were extracted from publications or calculated. After the administration of a single dose of MenACWY-TT, substantial IRRs of MenCWY were observed across the countries in vaccine-eligible age groups (83%-85%) and via indirect protection in non-vaccine-eligible age groups (45%-53%). The impact of MenACWY-TT was primarily driven by MenW IRRs, as seen in vaccine-eligible age groups (65%-92%) and non-vaccine-eligible age groups (41%-57%). VE against MenW was reported in vaccine-eligible toddlers (92%) in the Netherlands and in vaccine-eligible adolescents/young adults (94%) in England. These real-world data support the implementation and continued use of MenACWY-TT in NIPs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016628
003      
CZ-PrNML
005      
20231026105651.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/21645515.2023.2251825 $2 doi
035    __
$a (PubMed)37679903
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Villena, Rodolfo $u Department of Pediatrics, Faculty of Medicine, Universidad de Chile, Santiago, Chile $u Infectious Diseases Unit, Hospital de niños Dr. Exequiel González Cortés, Santiago, Chile
245    10
$a Real-world impact and effectiveness of MenACWY-TT / $c R. Villena, P. Kriz, M. Tin Tin Htar, C. Burman, J. Findlow, P. Balmer, L. Jodar
520    9_
$a In response to escalating cases of serogroup W (MenW) invasive meningococcal disease (IMD), multiple countries introduced quadrivalent conjugate MenACWY vaccines into their national immunization programs (NIPs). Here, we summarize the real-world impact and vaccine effectiveness (VE) data of MenACWY-TT from Chile, England, the Netherlands, and Australia. Incidence rate reductions (IRRs) and VE from baseline to post-NIP period were extracted from publications or calculated. After the administration of a single dose of MenACWY-TT, substantial IRRs of MenCWY were observed across the countries in vaccine-eligible age groups (83%-85%) and via indirect protection in non-vaccine-eligible age groups (45%-53%). The impact of MenACWY-TT was primarily driven by MenW IRRs, as seen in vaccine-eligible age groups (65%-92%) and non-vaccine-eligible age groups (41%-57%). VE against MenW was reported in vaccine-eligible toddlers (92%) in the Netherlands and in vaccine-eligible adolescents/young adults (94%) in England. These real-world data support the implementation and continued use of MenACWY-TT in NIPs.
650    _2
$a mladiství $7 D000293
650    _2
$a mladý dospělý $7 D055815
650    _2
$a lidé $7 D006801
650    12
$a meningokokové infekce $x epidemiologie $x prevence a kontrola $7 D008589
650    _2
$a kombinované vakcíny $7 D017778
651    _2
$a Austrálie $x epidemiologie $7 D001315
651    _2
$a Anglie $7 D004739
651    _2
$a Nizozemsko $x epidemiologie $7 D009426
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kriz, Paula $u Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Tin Tin Htar, Myint $u Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Paris, France
700    1_
$a Burman, Cindy $u Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA
700    1_
$a Findlow, Jamie $u Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Ltd, Tadworth, UK
700    1_
$a Balmer, Paul $u Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA
700    1_
$a Jodar, Luis $u Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA
773    0_
$w MED00181409 $t Human vaccines & immunotherapeutics $x 2164-554X $g Roč. 19, č. 2 (2023), s. 2251825
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37679903 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105646 $b ABA008
999    __
$a ok $b bmc $g 2000257 $s 1202990
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 19 $c 2 $d 2251825 $e 2023Aug01 $i 2164-554X $m Human vaccines & immunotherapeutics $n Hum Vaccin Immunother $x MED00181409
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Archiving options